Table 3 Key diagnostic procedures and PH-related pharmaceutical claims during follow-up by underlying lung disease
From: Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia
Therapy | Comorbid COPD | Comorbid ILD | Comorbid SDB | Comorbid DLD | ||||
|---|---|---|---|---|---|---|---|---|
Group 3 PH (n = 1590) | Controls (n = 1590) | Group 3 PH (n = 438) | Controls (n = 438) | Group 3 PH (n = 340) | Controls (n = 340) | Group 3 PH (n = 503) | Controls (n = 502) | |
Diagnostic Procedure | ||||||||
Echocardiography | 1181 (74.3) | 313 (19.7) | 340 (77.6) | 85 (19.4) | 252 (74.1) | 66(19.4) | 374 (74.4) | 124 (24.7) |
RHC | 92 (5.8) | 2 (0.1) | 32 (7.3) | 4 (0.9) | 16 (4.7) | 2 (0.6) | 32 (6.4) | 2 (0.4) |
Pharmaceutical Treatment | ||||||||
Oral anticoagulants | 642 (40.3) | 331 (20.8) | 137 (31.3) | 75 (17.1) | 122 (35.9) | 81 (23.8) | 197 (39.2) | 138 (27.5) |
Diuretics | 1084 (68.2) | 521 (32.8) | 236 (53.9) | 126 (28.8) | 224 (65.9) | 134 (39.4) | 359 (71.4) | 185 (36.9) |
Calcium channel blockers | 600 (37.7) | 428 (26.9) | 172 (39.3) | 147 (33.6) | 138 (40.6) | 105 (30.9) | 214 (42.5) | 154 (30.7) |
Digoxin | 194 (12.2) | 67 (4.2) | 46 (10.5) | 17 (3.9) | 22 (6.5) | 13 (3.8) | 64 (12.7) | 23 (4.6) |
Prostacyclin analogues | 22 (1.4) | 0 | 15 (3.4) | 0 | 4 (1.2) | 0 | 7 (1.4) | 0 |
ERAs | 137 (8.6) | 0 | 102 (23.3) | 0 | 25 (7.4) | 0 | 32 (6.4) | 0 |
PDE5 inhibitorsa | 255 (16.0) | 25 (1.6) | 136 (31.1) | 6 (1.4) | 39 (1.7) | 17 (0.8) | 74 (14.7) | 6 (1.2) |